Diligence memo · auto-generated · as of July 2, 2026
PeproMene Bio, Inc.
PeproMene Bio, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
PeproMene Bio, Inc. operates in Biotechnology, based in IRVINE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
PeproMene Bio, Inc. has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $40M on 2017-07-17.
Most recent recorded round closed around 2017-07-17.
Valuation (modeled)modeled
Provath models PeproMene Bio, Inc. at approximately $1.6B (range $124M–$4.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 79% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.